Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

INVA vs MLTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INVA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

INVA Overall Winner 6-Pillar Tally: INVA 5 – 1 MLTX Matrix Metrics: INVA 8 – 2 MLTX

As of Nov 16, 2026, Innoviva, Inc. (INVA) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INVA carries a Unified Composite Score of 48.9/100 (HOLD) at $18.59 (8.8x Forward P/E, 39.5% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: INVA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INVA vs MLTX
INVA NASDAQ Head-to-Head Winner
Innoviva, Inc. Common Stock
Pharmaceutical Preparations
$18.59
-2.34% 1D
Market Cap $1.3B
TTM Revenue $438M
Forward P/E 8.8x
Beta / 30D Vol 0.32β · 37% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 39.0 Fund 59.0 Flow 66.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.6%), weak momentum, RSI 29
RSI-14: 29.4 · SMA20: $20.23 · SMA50: $20.64
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82

6-Pillar Scorecard Institutional Category Breakdown (INVA 5 – 1 MLTX)

Columns: Metric · INVA · MLTX
1. Valuation Multiples INVA
Forward P/E 8.8x N/M
Trailing P/E 8.1x N/M
PEG Ratio 2.82x N/M
EV / Revenue 2.4x N/M
2. Growth & Scale INVA
Revenue Growth (YoY) -1.6% +0.0%
Earnings Growth (YoY) +590.4% +0.0%
TTM Revenue (USD) $438M N/A
Market Cap $1.3B $1.1B
3. Profitability & Quality INVA
Gross Margin 77.0% N/A
Operating Margin 39.5% 0.0%
Net Profit Margin 44.1% 0.0%
Return on Equity (ROE) 18.0% -81.5%
4. Balance Sheet & Cash Flow INVA
Cash Generation (TTM) $183M -$244M
Cash Flow Margin 41.6% N/A
Net Cash / Leverage $312M Net Cash $278M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLTX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 23.8% (4th %ile) 111.8% (7th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat INVA
OpEx & R&D Intensity 37.5% of Rev ($164M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INVA (8) vs MLTX (2)
Institutional Metric INVA MLTX Criterion Row Edge
Market Capitalization
Scale
$1.3B $1.1B Larger Scale INVA
Trailing P/E Ratio
Valuation
8.1x N/M Lower Multiple INVA
Forward P/E Ratio
Valuation
8.8x N/M Lower Multiple INVA
Revenue Growth (YoY)
Growth
-1.6% +0.0% Higher Growth MLTX
Operating Margin (TTM)
Profitability
39.5% 0.0% Higher Margin INVA
Net Profit Margin
Profitability
44.1% 0.0% Higher Margin INVA
Return on Equity (ROE)
Capital Efficiency
18.0% -81.5% Higher ROE INVA
52-Week Range Position
Momentum
2% ($18–$25) 17% ($9–$23) Stronger Trend MLTX
Beta / 30D Volatility
Risk Regime
0.32β · 37% Vol 1.61β · 90% Vol Lower Realized Risk INVA
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 38.3 / 100 (SELL) Higher Composite INVA
Trailing 12M Revenue (USD)
Operating Scale
$438M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
77.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.82x PEG · 2.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$183M ($312M Net Cash) -$244M ($278M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLTX +34.64 pp
INVA: -10.56% · MLTX: +24.08%
3M Horizon INVA +14.94 pp
INVA: -12.54% · MLTX: -27.48%
6M Horizon INVA +13.17 pp
INVA: -14.75% · MLTX: -27.92%
1Y Horizon MLTX +10.63 pp
INVA: -16.28% · MLTX: -5.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INVA vs MLTX. Trailing 12-month operating profitability (INVA 39.5% vs MLTX 0.0%) and valuation multiples (INVA 8.8x vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

INVA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$438M
Gross Margin77.0%
Op. Margin39.5%
ROE / Fwd P/E18.0% · 8.8x
MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INVA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 23.8%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact INVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INVA Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and 39.5% operating margin.
OpEx & R&D Reinvestment 37.5% of Rev ($164M)
90D Engineering Disclosures 0 Published
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ INVA vs MLTX Key Questions & Quantitative Answers

As of Nov 16, 2026, Innoviva, Inc. (INVA) is the stronger overall head-to-head candidate over MoonLake Immunotherapeutics Class A (MLTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). INVA carries a Unified Composite Score of 48.9/100 (HOLD) at $18.59 (8.8x Forward P/E, 39.5% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: INVA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.4); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INVA leads the Growth & Scale pillar: INVA posts -1.6% YoY revenue growth and +590.4% YoY earnings growth on $438M TTM revenue (77.0% gross margin, 39.5% operating margin), compared with MLTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, INVA generates $438M in USD-normalized revenue versus N/A for MLTX. In operating R&D and SG&A reinvestment, INVA deploys 37.5% of Rev ($164M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MLTX.

INVA screens cheaper on headline valuation multiples. INVA trades at 8.8x Forward P/E, 8.1x Trailing P/E, 2.82x PEG, and 2.4x EV/Revenue (41.6% FCF margin), whereas MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INVA (18.0% ROE) versus MLTX (-81.5% ROE) capital efficiency.

In options market volatility and institutional positioning, INVA carries 23.8% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 37% Vol realized risk). By comparison, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.